• Thinly traded cancer therapy developer Arcus Biosciences (RCUS+83.7%) is up big on almost a 7x surge in volume on reports that Gilead Sciences (GILD +2.0%) is mulling a "significant stake" in the company.
• The company's pipeline includes anti-TIGIT antibody AB154, PD-1 inhibitor zimberelimab and dual A2a/A2b adenosine receptor antagonist AB928.
• Alphabet's venture capital unit, GV, is also an investor.
Gilead up 6% after hours on remdesivir buzz in COVID-19
STAT reports that preliminary results from a study in Chicago evaluating Gilead Sciences' (NASDAQ:GILD) remdesivir in severely ill COVID-19 patients are positive with rapid recoveries in fever and respiratory symptoms observed and almost all patients discharged in less than a week.
